

## CYP2D6 Polyclonal Antibody

### Description

<b>Product type</b>	Primary Antibody
<b>Code</b>	BT-AP02410
<b>Host</b>	Rabbit
<b>Isotype</b>	IgG
<b>Size</b>	20ul, 50ul, 100ul
<b>Immunogen</b>	Synthesized peptide derived from the Internal region of human CYP2D6.
<b>Mol wt</b>	50054
<b>Species reactivity</b>	Human
<b>Clonality</b>	Polyclonal
<b>Recommended application</b>	WB, ELISA
<b>Concentration</b>	1 mg/ml
<b>Full name</b>	CYP2D6 Antibody
<b>Synonyms</b>	CYP2D6; CYP2DL1; Cytochrome P450 2D6; CYP11D6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase

**This product is for research use only, not for use in human, therapeutic or diagnostic procedure.**

### Background

CYP2D6 encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. Cytochrome P450 2D6 localizes to the endoplasmic reticulum and is known to metabolize as many as 25% of commonly prescribed drugs. Its substrates include antidepressants, antipsychotics, analgesics and antitussives, beta adrenergic blocking agents, antiarrhythmics and antiemetics. The gene is highly polymorphic in the human population; certain alleles result in the poor metabolizer phenotype, characterized by a decreased ability to metabolize the enzyme's substrates. Some individuals with the poor metabolizer phenotype have no functional protein since they carry 2 null alleles whereas in other individuals the gene is absent. CYP2D6 can vary in copy number and individuals with the ultrarapid metabolizer phenotype can have 3 or more active copies of the gene. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

### Recommended Dilution

WB: 1: 500 - 1: 2000

ELISA: 1: 40000

Not yet tested in other applications.

### Images

No images.

### Storage

-20°C for one year